NNE Pharmaplan
在场
NNE Pharmaplan 的所有者是 Novo Nordisk.
是其中之一......
- Forbes Global 2000 (#205);
- Fortune 500 Europe (#116);
- Global Fortune 500 (#469);
- Stoxx 600;
- TOB Iconic 10,000.
Novo Nordisk 是一家在股票代码 NOVO (DK) 下上市的公司。
Novo Nordisk 在 11 个国家有直接业务。Novo Nordisk 拥有 16家子公司，其中包括 Cardior Pharmaceuticals、Dicerna Pharmaceuticals 和 Inversago Pharma。
他们在：
涉及Novo Nordisk的并购和融资。
- Novo Nordisk has announced the acquisition of Inversago Pharma (公布2023八月15号).
高管
查看带有其 15 名主要高管的组织结构图
NNE Pharmaplan 搜索最多的简介
- Jesper Kløve, Chief Executive Officer
- Birgit Norgaard, Vice Chairman of the Board
- Inés Aréizaga Esteva, Director, Employee Representative
创建提醒
跟踪 NNE Pharmaplan 的高管变动
药店
Novo Nordisk 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
NNE Pharmaplan 的最新新闻稿
- Gazelle story 2024
- The annual report for 2023 reflects the best financial year in NNE history.
- NNE engineering partner on Novo Nordisk’s 42 billion kroner expansion in Kalundborg
- Press releases
- 2022 - An impressive financial year for NNE
- Another great financial year for NNE
- NNE is engineering partner on Novo Nordisk’s 17 bn expansion in Kalundborg
- Anette Yan Marcussen receives PDA Service Appreciation Award
- Sofie Jarl Mørck takes over at Chief Financial Officer | NNE
- Sofie Jarl Mørck takes over at Chief Financial Officer | NNE
- View more press releases Close
